Search Videos and More
News
Dana-Farber Researchers Chart a Course for Understanding, Preventing, and Treating Young-Onset Colorectal Cancer
Colorectal cancer among young people is increasing globally and rapidly. Experts expect it to become the leading cause of cancer death in individuals aged 20-49 in the U.S. by the year 2030.
News
Finding Pancreatic Cancer Earlier - How Dana-Farber is Transforming the Narrative in the Early Detection and Treatment of a Stubborn Cancer
Pancreatic cancer is notoriously difficult to treat. It's commonly discovered at an advanced stage with distant metastases. But innovations in genetic testing and early detection at Dana-Farber are transforming this narrative — giving patients renewed hope for successful long-term treatment and even cures.
News
Study Unravels a Cause of Resistance to Novel Drug in Patients with Acute Leukemia
A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
News
Study Suggests Possible Way to ‘Smac’ Cancer
In a new study, researchers at Dana-Farber Cancer Institute used cryo-electron microscopy to reveal for the first time how one IAP, a protein called BIRC6, operates at a molecular level to inhibit programmed cell death.
News
Dana-Farber Led Study Leads to FDA Approval for Next-Generation Drug in Relapsed Chronic Lymphocytic Leukemia
On Thursday, January 19, 2023, the FDA approved zanubrutinib, a next-generation BTK inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
News
Study Finds Racial Inequities in Access to Opioids Among Older Patients With Cancer Near End of Life
Older Black and Hispanic patients with advanced cancer are less likely to receive opioid medications for pain relief in the last weeks of life than White patients, a new study led by Dana-Farber Cancer Institute investigators found.
News
Research With a Worldwide Reach
Around the world, Dana-Farber's Susan F. Smith Center for Women's Cancers is known not just for its exceptional patient care, but also for the driving force its physician-scientists play in developing new paradigms of cancer treatment through pioneering research and clinical trials.
News
New International Partnership to Accelerate Search for Cancer Cures
Cancer patients in Australia and the United States will benefit from a new research-focused collaboration between the Peter MacCallum Cancer Centre and Dana-Farber Cancer Institute in Boston.
News
Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment
In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes in immune system cells can indicate which patients with high-risk "smoldering" myeloma are likely to progress to myeloma and which will benefit the most from treatment.
Video
Multiple Myeloma Research: Risks, Benefits of Stem Cell Transplant
Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later.
Video
ASCO2022: Multiple Myeloma Research by Dr. Paul Richardson
Dana-Farber research into autologous stem cell transplant for patients with multiple myeloma: a study led by Dr. Paul G. Richardson, MD, found patients had dramatically increased progression-free survival, but were just as likely to be alive more than 6 years later if they chose to reserve their transplant until later.
News
New Protein Complex Structure Reveals Possible Ways To Target Key Cancer Pathway
Scientists have solved the structure of an important complex of RAS-pathway proteins, explaining how known mutations lead to disease and suggesting potential new binding sites for cancer drugs.